Synoptical view

    Truffle investment
    € 15M
    Pharnext is listed on EURONEXT GROWTH PARIS since 2016

Management team

Board of Directors

President Emmanuel Macron congratulates Carbios on the 2nd anniversary of France 2030, Vexim (MedTech acquired by Stricker for $200 million), Carmat, Symetis (MedTech acquired by Boston Scientific for $430 million), Affluent Medical (MedTech, listed on the stock exchange), Diaccurate and Caranx Medical.

As a former Paris hospital intern in immunology and hematology, Dr Pouletty holds a doctorate in medicine from the University of Paris VI and a master's degree in immunology and virology from the Institut Pasteur. He was a post-doctoral researcher (1986-1988) at Stanford University.

He is the winner of the 1999 American Liver Foundation Award. Doctor Philippe Pouletty is a Chevalier de la Légion d'Honneur.


Philippe Pouletty, M.D.

Co-Founder & CEO at Truffle Capital

In summary

Pharnext has two flagship products in clinical development, one for the treatment of Charcot-Marie-Tooth disease type 1A, the other for the treatment of Alzeimer's disease. Pharnext has developed a new paradigm for drug discovery based on large genomic data and artificial intelligence: PLEOTHERAPY. The company identifies and develops synergistic drug combinations


Press Release

Pharnext Announces Identification of a Large Set of Frequently Prescribed Drugs to be Repurposed for Fighting COVID-19


Next start-up